O121 Sci-B-Vac Is Superior to Engerix-B for Preventing HBV Vertical Transmission

Saed, Nizar; Hakim, MSc. Prof.Dr. Lukman; Nijim, Y.; Farah, Naima; Jamalia, J; Nuser, Tawfik; Ismael, K Mohamad; Ghantous, R.; Amer, J.; Safadi, R.

doi:10.1016/s0168-8278(14)60123-9

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Engerix-B, 16 and is able to induce preS1 antibodies in newborns. 40 Our data does not provide evidence for a significant difference in anti-HBs response attributed to vaccine type (p D 0.736), however, it does not exclude a superior protection efficacy of Sci-B-Vac as recently suggested by Saed et al 17 In contrast to other studies 5,21 our results did not suggest that mounting an anamnestic immune response was age dependent (p D 0.392). In line with Zanetti et al, 25 but contrary to McMahon et al 41 , anti-HBs immune response in our study was not gender dependent either (p D 0.283, pre-challenge and p D 0.366, post-challenge).…”

Section: Discussioncontrasting

confidence: 87%

“…A total of 257 children (2-19 years old) with anti-HBs titers below 100 mIU/ml were subjected to a challenge dose of either Sci-B-Vac (SciGen) or Engerix-B (GSK) administered by intramuscular injection into the deltoid muscle. For the age group 2-10 5 mg Sci-B-Vac (LOT: B0332V1) was used while 10 mg Sci-B-Vac (LOT: B0361V1) was used for ages [11][12][13][14][15][16][17][18][19] according to manufacturer instructions. The dose for Engerix-B (LOT: AHBVC007BK) was 0.5 ml (10 mg) for the age group 2-10 years and 1 ml (20 mg) for ages 11-19 according to manufacturer instructions.…”

Section: Methodsmentioning

confidence: 99%

“…16 More recent preliminary findings suggest that it protects passively immunized newborns from HBV positive mothers more effectively than Engerix-B. 17 Generally, administration of the vaccine in either form results in protective antibodies in early stages of life, but maintaining the protective immunity among vaccinees in late childhood and adulthood raises issues regarding the introduction of booster HBV vaccine. [18][19][20][21][22] In contrast, other studies have shown persistence of immunity for periods of 9-15 years.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Age-dependent decrease of anti-HBs titers and effect of booster doses using 2 different vaccines in Palestinian children vaccinated in early childhood

Qawasmi

Samuh

Glebe

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Immunization against hepatitis B virus (HBV) has proven to be highly effective and led to significant reduction of new infections worldwide. However, protective immunity measured by anti-HBs titers may decrease to critical levels in the years after basal immunization, particularly in case of exposure to HBV variants different from the vaccine strain. We tested 400 Palestinian children between one and 19 years of age for their anti-HBs titer, challenged the immune memory of those with low or absent anti-HBs with 2 types of hepatitis B vaccines and determined thereafter the anti-HBs titer. At the age of one, 92.2% of the children presented with protective anti-HBs titers (≥ 10 mIU/ml) with the majority having ≥ 100 mIU/ml. Protective immunity was still high at ages 2 (87.5%) and 4 (95%), declining by age 5 and 6 (from 69.2% to 66.7%) and down to an average of 39.8% between the ages of 7 and 19. 160 children with a nonprotective or low immune response challenged with either the yeast-derived Engerix-B or the mammalian cell-derived preS1-containing Sci-B-Vac vaccine showed an anamnestic immune response. 92.4% and 85.9% of the children challenged with one dose Sci-B-Vac and Engerix-B presented with anti-HBs titers >100 mIU/ml respectively. Our results reveal that vaccine-induced protective anti-HBs titers against HBV decrease rapidly beyond the age of 6 in Palestinian children, but can be strongly enhanced with a single booster vaccine dose, independent of brand and antigen composition. Our data suggest that a booster vaccine dose against HBV during school years may be useful.

show abstract

Section: Discussioncontrasting

confidence: 87%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Age-dependent decrease of anti-HBs titers and effect of booster doses using 2 different vaccines in Palestinian children vaccinated in early childhood

Qawasmi

Samuh

Glebe

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Reviewed in [58] Health/disease status Chronic kidney disease [59,60] Haemodialysis [61,62] Diabetes [63] HIV [64,65] Hematopoietic stem cell recipients [66] Pre-existing hepatitis C infection [67,68] in this special issue of Medical Microbiology and Immunology [22,23] (see also articles from D. Shouval et al and from W. Gerlich in this issue). In the following sections, we will focus on the effects of adjuvants on the magnitude and qualities of the immune response to the vaccine antigen, HBsAg.…”

Section: Strategies To Improve Protection Elicited By Hepatitis B Vacmentioning

confidence: 99%

Old and new adjuvants for hepatitis B vaccines

Leroux‐Roels

2014

Med Microbiol Immunol

View full text Add to dashboard Cite

The safety and immunogenicity profiles of currently available recombinant hepatitis B vaccines are excellent. However, it remains a real challenge to induce protective immunity in the target groups that respond poorly or not at all to conventional vaccines. Ideally, a hepatitis B vaccine can be developed that conveys lifelong protection against infection rapidly after the injection of a single dose. Although this goal is far from being reached, important improvements have been made. Novel vaccine adjuvants have been developed that enhance the immunogenicity of recombinant hepatitis B vaccines while maintaining a good safety profile. The different adjuvants and adjuvant systems that are discussed herein have all been thoroughly evaluated in clinical trials and some have reached or are close to reach the market.

show abstract

Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives

Gerlich

2014

Med Microbiol Immunol

View full text Add to dashboard Cite

Large-scale vaccination against hepatitis B virus (HBV) infection started in 1984 with first-generation vaccines made from plasma of chronic carriers containing HBV surface antigen (HBsAg). Thereafter, it was replaced in most countries by second-generation vaccines manufactured in yeast cells transformed with gene S encoding HBsAg. Both generations of vaccines have been applied for universal neonate and early childhood vaccination worldwide and have led to a 70-90 % decrease in chronic HBV carrier rates. However, 10-30% of newborns from HBsAg/HBeAg-positive mothers cannot be protected by passive/active vaccination alone and become chronic HBV carriers themselves. Asymptomatic occult HBV infections are frequent even in those who have protective levels of anti-HBs. Suboptimal protection may be due to heterologous HBsAg subtypes that are present in 99% of HBV carriers worldwide. Second-generation vaccines contain partially misfolded HBsAg and lack preS1 antigen that carries the major HBV attachment site and neutralizing epitopes. Third-generation vaccines produced in mammalian cells contain correctly folded HBsAg and neutralizing epitopes of the preS antigens, induce more rapid protection, overcome nonresponse to second-generation vaccines and, most importantly, may provide better protection for newborns of HBV-positive mothers. PreS/S vaccines expressed in mammalian cells are more expensive to manufacture, but introduction of more potent HBV vaccines should be considered in regions with a high rate of vertical transmission pending assessment of health economics and healthcare priorities. With optimal vaccines and vaccination coverage, eradication of HBV would be possible.

show abstract

O121 Sci-B-Vac Is Superior to Engerix-B for Preventing HBV Vertical Transmission

Cited by 5 publications

References 0 publications

Age-dependent decrease of anti-HBs titers and effect of booster doses using 2 different vaccines in Palestinian children vaccinated in early childhood

Age-dependent decrease of anti-HBs titers and effect of booster doses using 2 different vaccines in Palestinian children vaccinated in early childhood

Old and new adjuvants for hepatitis B vaccines

Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives

Contact Info

Product

Resources

About